


Searching News Database: BRAF
HSMN NewsFeed - 10 Aug 2026
Labcorp Announces FDA Approval of Companion Diagnostic Supporting Patients with Advanced Melanoma
Labcorp Announces FDA Approval of Companion Diagnostic Supporting Patients with Advanced Melanoma
HSMN NewsFeed - 8 Sep 2020
FDA Approves First NGS-Based Companion Diagnostic for RET Fusion-Positive Non-Small Cell Lung Cancer
FDA Approves First NGS-Based Companion Diagnostic for RET Fusion-Positive Non-Small Cell Lung Cancer
HSMN NewsFeed - 26 Feb 2019
Thermo Fisher Scientific's Oncomine Dx Target Test Receives Expanded Regulatory Approval in Japan
Thermo Fisher Scientific's Oncomine Dx Target Test Receives Expanded Regulatory Approval in Japan
HSMN NewsFeed - 30 May 2017
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
HSMN NewsFeed - 20 Jan 2017
Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer
Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer
HSMN NewsFeed - 28 Jul 2016
Array BioPharma Announces Appointment Of Jason Haddock As Chief Financial Officer
Array BioPharma Announces Appointment Of Jason Haddock As Chief Financial Officer
HSMN NewsFeed - 10 Dec 2015
Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA(R) Combination Trial
Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA(R) Combination Trial
HSMN NewsFeed - 14 Jul 2015
Biocept Launches Diagnostic Assay for BRAF Mutations in Patients with Melanoma
Biocept Launches Diagnostic Assay for BRAF Mutations in Patients with Melanoma
HSMN NewsFeed - 26 May 2015
Roche receives FDA clearance for the cobas(R) Cdiff Test to detect Clostridium difficile
Roche receives FDA clearance for the cobas(R) Cdiff Test to detect Clostridium difficile
HSMN NewsFeed - 14 May 2014
Agios Pharmaceuticals Appoints Chris Bowden, M.D., as Chief Medical Officer
Agios Pharmaceuticals Appoints Chris Bowden, M.D., as Chief Medical Officer
HSMN NewsFeed - 24 Apr 2014
FDA Approves Roche's HPV Test for First-Line Primary Screening for Cervical Cancer
FDA Approves Roche's HPV Test for First-Line Primary Screening for Cervical Cancer
HSMN NewsFeed - 1 Oct 2013
First urine-based cancer mutation monitoring test available from Trovagene
First urine-based cancer mutation monitoring test available from Trovagene
HSMN NewsFeed - 28 Nov 2012
Trovagene to Introduce First Urine-Based Molecular Diagnostic Test for Transrenal Cancer Mutation Monitoring
Trovagene to Introduce First Urine-Based Molecular Diagnostic Test for Transrenal Cancer Mutation Monitoring
HSMN NewsFeed - 16 May 2012
Genentech Will Report New Data on Important Progress for People with Advanced Cancers at ASCO 2012
Genentech Will Report New Data on Important Progress for People with Advanced Cancers at ASCO 2012
HSMN NewsFeed - 16 Nov 2011
Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
HSMN NewsFeed - 7 Sep 2011
TrovaGene, Inc., Announces Worldwide Exclusive Licensing of Assay for Hairy Cell Leukemia
TrovaGene, Inc., Announces Worldwide Exclusive Licensing of Assay for Hairy Cell Leukemia
HSMN NewsFeed - 19 Jan 2011
Genentech Personalized Investigational Medicine Shows Survival Benefit in Advanced Skin Cancer
Genentech Personalized Investigational Medicine Shows Survival Benefit in Advanced Skin Cancer
HSMN NewsFeed - 22 Mar 2010
Asuragen Appoints French Distributor Biomedical Diagnostics SA for Signature(R) Oncology Portfolio
Asuragen Appoints French Distributor Biomedical Diagnostics SA for Signature(R) Oncology Portfolio
HSMN NewsFeed - 3 Oct 2008
Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement
Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement
HSMN NewsFeed - 4 Oct 2006
Plexxikon and Roche Enter Partnership to Develop Targeted Cancer Therapeutic Medicine PLX4032
Plexxikon and Roche Enter Partnership to Develop Targeted Cancer Therapeutic Medicine PLX4032
